Atropine Management for Symptomatic Bradycardia During Emergency Tracheostomy

Immediate Assessment of Symptomatic Bradycardia

Identify hemodynamic compromise before treatment—altered mental status, systolic blood pressure < 80–90 mmHg, signs of shock (poor perfusion, cold extremities, delayed capillary refill), acute heart‑failure symptoms (dyspnea, pulmonary edema), or ischemic chest discomfort—each indicating symptomatic bradycardia that warrants atropine. [American Heart Association] [1]

First‑line dose: 0.5 – 1 mg atropine IV push given immediately when symptomatic bradycardia or new heart block is recognized during emergency tracheostomy. Repeat every 3–5 minutes as needed, not exceeding a cumulative total of 3 mg. [American Heart Association] [1]
Critical warning: Doses < 0.5 mg should be avoided because sub‑therapeutic amounts may paradoxically worsen bradycardia via a parasympathomimetic response. [American College of Cardiology; American Heart Association] [2]1
Maximum cumulative dose: 3 mg total (approximately 3–4 repeat doses). Exceeding this limit provides no additional benefit and raises the risk of central anticholinergic toxicity. [American College of Cardiology; American Heart Association] [2]1

Nodal‑level blocks likely to respond to atropine:
These arrhythmias typically improve with the recommended atropine regimen. [American College of Cardiology; American Heart Association] [2]1
Infranodal blocks unlikely to respond to atropine:
In these cases, atropine is ineffective and alternative pacing or pharmacologic support should be pursued promptly. [American College of Cardiology; American Heart Association] [2]1

Transcutaneous pacing (TCP): Do not delay TCP in hemodynamically unstable patients; apply pacing pads after the first or second atropine dose if the heart rate remains inadequate. [American Heart Association; American College of Cardiology] [1]2
Chronotropic infusions (if TCP unavailable or ineffective):
Both agents are recommended as rescue therapy after failed atropine and/or pacing. [American Heart Association] [1]

Vagal mechanism in the tracheostomy setting: Bradycardia during emergency tracheostomy is frequently vagally mediated by airway manipulation, making atropine especially effective as the first‑line agent. [American College of Cardiology; American Heart Association] [2]1
Do not withhold atropine despite theoretical increase in myocardial oxygen demand; the immediate threat of hemodynamic collapse outweighs this concern. [American College of Cardiology] [2]
Futility threshold: If heart rate does not rise after a total of 1.5–2 mg atropine (approximately 3–4 doses), the underlying block is likely infranodal; promptly transition to TCP or chronotropic infusions. [American Heart Association] [1]
Timing of administration: Once IV access is secured, give atropine immediately upon recognition of symptomatic bradycardia; do not let the drug delay airway securing. [American Heart Association] [1]
Preparation for escalation: In high‑risk patients (e.g., elderly, known cardiac disease, severe hypoxia), place TCP pads prophylactically before beginning the tracheostomy to enable instant pacing if atropine fails. [American College of Cardiology] [2]

Symptomatic bradycardia is characterized by signs of hemodynamic instability including acute altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock 3, 4
Not all bradycardias require treatment - asymptomatic or minimally symptomatic patients may not need intervention unless the rhythm is likely to progress to symptoms or become life-threatening 4

The American Heart Association recommends administering atropine 0.5-1 mg IV for symptomatic bradycardia 3, 5
Repeat every 3-5 minutes as needed up to a maximum total dose of 3 mg 3, 5

Initiate transcutaneous pacing (TCP) in unstable patients who do not respond to atropine 3, 6, 7
Consider IV infusion of β-adrenergic agonists with rate-accelerating effects, such as dopamine (2-10 μg/kg/min) or epinephrine (2-10 μg/min) 3, 5, 6, 7

Atropine is most effective in sinus bradycardia, conduction block at the AV node level, or sinus arrest 3
Atropine may be ineffective in type II second-degree or third-degree AV block with new wide-QRS complex (block in non-nodal tissue) 3, 4

Use atropine cautiously in patients with acute coronary ischemia or MI, as increased heart rate may worsen ischemia or increase infarction size 3, 4
Atropine may be ineffective in heart transplant patients due to lack of vagal innervation 3, 4

Atropine administration should not delay implementation of external pacing for patients with poor perfusion 3
Immediate pacing might be considered in unstable patients with high-degree AV block when IV access is not available 6, 7

Clinical trials have shown that IV atropine improves heart rate, symptoms, and signs associated with bradycardia 3, 5

Continue cardiac monitoring during and after treatment 3, 6, 8
Evaluate response to therapy by monitoring heart rate, blood pressure, and resolution of symptoms 8
Be prepared to escalate to more advanced interventions if the patient's condition deteriorates 3, 6